Achieve Life Sciences, Inc. , a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today ...
Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...
( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Herpes Zoster (Shingles) - Global Clinical Trials Review, 2024" clinical trials has been added to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback